Trial
NCT02220088
The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Sun Yat-sen University
Collaborators
Kaiping Central Hospital; Guangzhou No.12 People's Hospital
Condition
Hepatocellular Carcinoma
Intervention
TAI of FOLFOX
Why stopped
protocol violation
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-01-11